News 1+1丨How to speed up the vaccination of Kexing Vaccine "WTO"? One article to understand →
As of June 3, 31 provinces, autonomous regions and municipalities directly under the Central Government and Xinjiang Production and Construction Corps have reported a total of 723 million vaccinations against the new crown virus.
On June 1, local time, the World Health Organization announced that China's Kexing new crown vaccine was included in the "emergency use list."
When can people aged 3~18 be vaccinated?
How to speed up vaccination?
In this issue of "News 1+1", Bai Yansong connects Yin Weidong, chairman of Kexing Holding Biotechnology Co., Ltd., to pay attention to it.
Kexing vaccine officially passed the WHO emergency use certification
Yin Weidong, Chairman of Kexing Holding Biotechnology Co., Ltd.:
Kexing
Zhongwei
has entered the WHO emergency use list and is the 47th emergency use obtained. Prior to this, Kexing has obtained emergency use in 46 countries outside of China. .
This means that it can meet the production quality standards of more countries, and it can also provide vaccines to more countries.
There are many countries that do not have the basis and conditions for vaccine review, so they will accept WHO certification before they can purchase; there is also a more important point that some international organizations, such as the COVAX global new crown vaccine plan, have passed such demonstrations. To purchase, for Kexing, it means providing vaccines to more countries on a larger scale.
Kexing Vaccine already has the capacity to provide vaccines to more countries with production preparation and production capacity increase conditions
Yin Weidong, Chairman of Kexing Holding Biotechnology Co., Ltd.:
When designing vaccine production capacity, China’s needs and global needs have been taken into consideration. Currently, Kexing Zhongwei’s design capacity is 2 billion per year.
However, according to the situation in the first half of this year, the production capacity has exceeded the designed production capacity.
We have now provided more than 600 million doses of vaccines to the world, which means that we have the quality standards for providing vaccines to the WHO and more countries and the conditions for further improvement in production preparation and production capacity.
The country has approved the emergency use of Kexing's new crown vaccine to expand the age range to over 3 years old
Yin Weidong, Chairman of Kexing Holding Biotechnology Co., Ltd.:
Kexing
Zhongwei
has a clinical study on the minor population, which has been launched at the beginning of this year, and has completed the first and second clinical trials, and hundreds of clinical studies have shown that After vaccination in the children group (3-17 years old), its safety is good, as safe as the 18-year-old adult group.
At the same time, the antibody level is the same as that of an adult.
The safety and effectiveness data has been reported to the Joint Prevention and Control Mechanism and the National Food and Drug Administration. We have submitted an application for emergency use of the vaccine. Now the country has approved the emergency use of Kexing's new crown vaccine to expand the age range to over 3 years old, but what is the vaccine? When it is used in lower age groups, the National Health Commission will organize relevant experts to promote the use of vaccines in different age groups in an orderly manner based on the needs of the current epidemic in China and the composition of the population.
The elderly are safe and effective after being vaccinated
Yin Weidong, Chairman of Kexing Holding Biotechnology Co., Ltd.:
In the third phase of the clinical study, the elderly over 60 years old group has been involved, but when Kexing vaccine is applied in the real world, especially in Chile, Brazil, and Turkey. In more serious countries, their immunization strategy is from a high age, starting from the age of 100, so large-scale real-world data have now been obtained.
The data currently obtained in Chile and Brazil are mainly composed of elderly people. It has fully shown that after the elderly are vaccinated, not only is the safety very reliable, but the protection effect is also very good.
The speed of vaccination has these four factors
Yin Weidong, Chairman of Kexing Holding Biotechnology Co., Ltd.:
①The safety of vaccines. As the public vaccinates, more and more safe vaccines will greatly increase the vaccination rate; ②During the vaccination process, the vaccine effect has also become the public The willingness to vaccinate, the real-world data recently reported in Brazil, Indonesia, and Chile has greatly promoted the public’s vaccination; ③The quantity of vaccine supply, through investigations in Zhejiang and other places, found that the public’s willingness to vaccinate is high, but The speed of supply is sometimes not enough. Now we have increased the monthly supply to hundreds of millions of doses. At this time, we can guarantee that the public can get the vaccine in time when they are willing to vaccinate; ④The government is very effective in organizing medical staff to work overtime Plus, even in meeting the wishes of the public day and night, these four elements can guarantee the immunity of rapid populations.
China's mass vaccination is expected to exceed 1 billion doses by the end of June
Yin Weidong, Chairman of Kexing Holding Biotechnology Co., Ltd.:
Organizing such a large-scale vaccination in China is a very complicated process. As a major supplier of vaccines, Kexing has adjusted the number of vaccine supplies after this year, focusing on domestic supply. Because a very important situation has emerged in China, that is, most people are in an immunization gap. Therefore, we have Provide vaccines on a large scale to quickly complete domestic vaccination. Judging from the current situation, at the end of June, we are very confident that through the provision of vaccines, we can protect 560 million people in our country, that is, more than 1 billion doses of vaccination.